Axa
RCUS icon

Axa’s Arcus Biosciences RCUS Stock Holding History

Axa’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-231,978
Closed -$1.89M – 824
2025
Q2 		$1.89M Buy
231,978
+370
+0.2% +$3.16K 0.01% 781
2025
Q1 		$1.82M Sell
231,608
-294
-0.1% -$3.41K 0.01% 754
2024
Q4 		$3.45M Sell
231,902
-364
-0.2% -$5.94K 0.01% 642
2024
Q3 		$3.55M Buy
232,266
+66
+0% +$1.04K 0.01% 632
2024
Q2 		$3.54M Buy
232,200
+128
+0.1% +$2.07K 0.01% 624
2024
Q1 		$4.38M Buy
232,072
+63
+0% +$1.09K 0.01% 587
2023
Q4 		$4.43M Sell
232,009
-5,610
-2% -$89.7K 0.01% 576
2023
Q3 		$4.27M Buy
237,619
+89,450
+60% +$1.8M 0.02% 564
2023
Q2 		$3.01M Buy
148,169
+2,038
+1% +$38.8K 0.01% 651
2023
Q1 		$2.67M Sell
146,131
-320
-0.2% -$6.12K 0.01% 704
2022
Q4 		$3.03M Sell
146,451
-885
-0.6% -$24.4K 0.01% 704
2022
Q3 		$3.85M Sell
147,336
-44,074
-23% -$1.17M 0.02% 634
2022
Q2 		$4.85M Buy
191,410
+56,895
+42% +$1.39M 0.02% 589
2022
Q1 		$4.25M Hold
134,515
– – 0.01% 691
2021
Q4 		$5.44M Buy
+134,515
New +$5.22M 0.01% 644

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's RCUS Position: Q3 2025 in Review

Axa sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 231,978 shares — an estimated $1.89M sold.

Axa first reported a position in RCUS in Q4 2021 and held it in 15 quarters. The position peaked at $5.44M in Q4 2021. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • Axa reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • Axa sold 231,978 Arcus Biosciences shares in Q3 2025, an estimated $1.89M.
  • Axa first reported a position in Arcus Biosciences in Q4 2021 and held it in 15 quarters.
  • Axa's Arcus Biosciences position peaked at $5.44M in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.